China Life Private Equity Investment led a $79m Series A round in Huisheng Biopharmaceutical.

Synopsis

China Life Private Equity Investment, a private equity firm, led a $79m Series A round in Huisheng Biopharmaceutical, a biopharmaceutical company, with participation from Tianjin Grand Flight and Ginkgo Capital.

Principals

target

Huisheng Biopharmaceutical

bidder

Tianjin Grand Flight

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Bidder Team (1)

jerry huang

Executive Director at CHINA LIFE PRIVATE EQUITY INVESTMENT

Investor

bidder

Deal

£ 62 M

Total Value

Vendor Team (1)

che fengsheng

Chairman at SIHUAN PHARMACEUTICAL

Manager

vendor

Deals

£ 151 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy